Aprea Therapeutics, Inc. — Net Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a0406f7a-3f5b-4b83-8210-3c2baf1712e3/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-12.6M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-028068 |
| FY 2024 | $-13.0M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-003588 |
| FY 2023 | $-14.3M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-003886 |
| FY 2022 | $-112.7M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-005126 |
| FY 2021 | $-37.1M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-003671 |
| FY 2020 | $-53.5M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-003083 |
| FY 2019 | $-28.1M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-003257 |
| FY 2018 | $-15.5M | 2018-01-01 – 2018-12-31 | evidence 0001558370-20-003257 |
| FY 2017 | $-15.2M | 2017-01-01 – 2017-12-31 | evidence 0001558370-20-003257 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).